Go Deep
ImmuCell Corporation
ImmuCell Corporation Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,735 | 153.6 | 3.11 | 0.40 | 1,020.69 |
| Oct 2026 | 20,844 | 150.9 | 3.06 | 0.40 | 1,002.79 |
| Oct 2026 | 20,735 | 153.6 | 3.11 | 0.40 | 1,018.19 |
| Oct 2026 | 20,273 | 150.1 | 3.04 | 0.40 | 996.52 |
| Oct 2026 | 20,307 | 149.3 | 3.02 | 0.40 | 990.83 |
| Oct 2026 | 20,267 | 150.3 | 3.04 | 0.40 | 995.00 |
| Oct 2026 | 20,313 | 149.1 | 3.02 | 0.40 | 985.44 |
ImmuCell Corporation Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 7,186,113.0 | 10,357,295.0 | 7,625,999.0 | 5,506,122.0 |
| Net Profit | 1,834,656.0 | 1,941,607.0 | -2,849,142.0 | -139,748.0 |
| EPS | 0.2 | 0.2 | -0.3 | -0.0 |
ImmuCell Corporation Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 27,644,174.0 | 26,493,169.0 | 17,471,669.0 | 18,567,962.0 |
| Net Profit | -1,040,027.0 | -2,156,629.0 | -5,774,598.0 | -2,493,805.0 |
| EPS | -0.1 | -0.3 | -0.8 | -0.3 |
ImmuCell Corporation Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 42,532,447.0 | 45,100,477.0 | 43,808,102.0 | 44,860,649.0 | — |
| Total Liabilities | 15,476,967.0 | 17,582,290.0 | 18,815,025.0 | 14,480,600.0 | — |
| Total Equity | 27,055,480.0 | 27,518,187.0 | 24,993,077.0 | 30,380,049.0 | — |
Owes vs Owns
ImmuCell Corporation owed $0.33 for every $1 it owned in Jun 2026, about the same as $0.32 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.33× | 0.36× | 0.39× | 0.43× | 0.32× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
ImmuCell Corporation Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 9.0%Receivables 8.1%Inventory 21.8%Fixed assets (tangible) 59.8%Other assets 1.1%
How it's funded — Dec 2025
Short-term debt 3.8%Long-term debt 17.6%Payables 1.9%Other liabilities 13.1%Shareholders' equity 63.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 3.8 | 3.8 | 1.0 | 5.8 |
| Receivables | 3.5 | 3.8 | 2.2 | 1.8 |
| Inventory | 9.3 | 7.1 | 7.8 | 6.0 |
| Fixed assets (tangible) | 25.5 | 29.9 | 32.1 | 30.6 |
| Intangible assets | 0.1 | 0.1 | 0.1 | 0.2 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.5 | 0.4 | 0.5 | 0.4 |
| Liabilities & equity | ||||
| Short-term debt | 1.6 | 1.5 | 1.4 | 1.0 |
| Long-term debt | 7.5 | 9.0 | 10.5 | 9.2 |
| Payables | 0.8 | 0.9 | 0.9 | 0.8 |
| Other liabilities | 5.6 | 6.1 | 6.0 | 3.5 |
| Shareholders' equity | 27.1 | 27.5 | 25.0 | 30.4 |
| Net tangible assets | 27.0 | 27.4 | 24.9 | 30.2 |
ImmuCell Corporation Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 2,475,292.0 | 357,903.0 | -4,674,236.0 | -1,543,871.0 | — |
| Investing Activities | -1,214,307.0 | -461,225.0 | -1,890,039.0 | -3,964,274.0 | — |
| Financing Activities | -1,212,386.0 | 2,882,813.0 | 1,751,454.0 | 1,114,239.0 | — |